Study Highlights Laboratory Parameters in 4 Years of Psoriasis Treatment with Deucravacitinib
HCPLive
SEPTEMBER 16, 2024
These poster data presented at the Maui Derm Fall 2024 conference highlight changes in laboratory parameters for patients using the TYK2 inhibitor deucravacitinib.
Let's personalize your content